The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis
- 1 March 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 20 (2), 138-144
- https://doi.org/10.1097/bor.0b013e3282f4b392
Abstract
Anti-tumour necrosis factor therapy has proven effective as treatment against a series of autoimmune inflammatory diseases, and has displayed a rapidly increasing market penetration. The safety profile of these drugs is, however, both uncertain and debated, in particular with respect to infections and malignancy. Lack of uniform definitions and methods of analysis makes it difficult to directly compare data from randomized controlled trials, meta-analyses of trials, open-label extensions, data from spontaneous reporting, and particularly, observational cohort studies. In this review, we provide a summary of currently published data on infection, malignancy, cardiovascular disease, interstitial lung disease, and death in relation to treatment of rheumatoid arthritis with anti-tumour necrosis factor agents. Superficially contradictory data on infection display a more or less coherent pattern of an increased risk shortly after treatment starts. Available data on malignancy, cardiovascular disease, interstitial lung disease, and death do not exclude clinically important increased risks, nor do they refute beneficial effects. Harmonized methods of reporting safety data would greatly improve the interpretation and comparison of class and drug-specific risks.Keywords
This publication has 48 references indexed in Scilit:
- Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonistsAnnals Of The Rheumatic Diseases, 2007
- Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritisArthritis & Rheumatism, 2007
- Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritisRheumatology, 2007
- Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonistsArthritis & Rheumatism, 2007
- Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Infections in patients with rheumatoid arthritis treated with biologic agentsArthritis & Rheumatism, 2005
- Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trialArthritis & Rheumatism, 2004
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trialArthritis & Rheumatism, 2004
- Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2004